NCT07322419 Hemodynamics During Cesarean Delivery Under Spinal Anesthesia With Norepinephrine Versus Ephedrine
| NCT ID | NCT07322419 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Mansoura University |
| Condition | Cesarean Delivery |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2026-01-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 200 participants in total. It began in 2026-01-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Echocardiography will be used to measure cardiac output and calculate other important hemodynamic variables in healthy patients with full-term singleton pregnancy during cesarean delivery under conventional spinal anesthesia using 2 different vasopressor drugs: norepinephrine in 1 group versus ephedrine in another group.
Eligibility Criteria
Inclusion Criteria: * American Society of Anesthesiologists physical status II. * Singleton, full term pregnancy. * Scheduled cesarean delivery under spinal anesthesia. Exclusion Criteria: * Height \<150 or \>180 cm. * Weight \<60 or \>110 kg. * Body mass index (BMI) \<18.5 or ≥35 kg/m². * Women presenting in labor. * Any contraindication to spinal anesthesia: increased intracranial pressure, coagulopathy, or local skin infection. * Chronic or pregnancy-induced hypertension. * Baseline systolic blood pressure \>140 mm Hg. * Hemoglobin \<10 g/dl. * Diabetes mellitus, cardiovascular, cerebrovascular, or renal disease. * Polyhydramnios or known significant fetal abnormalities. * Current administration of vasoactive drugs such as: beta blockers, salbutamol, or thyroxin.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07322419 clinical trial?
This trial is open to female participants only, aged 19 Years or older, up to 40 Years, studying Cesarean Delivery. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07322419 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07322419 currently recruiting?
Yes, NCT07322419 is actively recruiting participants. Contact the research team at m2tawfik@mans.edu.eg for enrollment information.
Where is the NCT07322419 trial being conducted?
This trial is being conducted at Al Mansurah, Egypt.
Who is sponsoring the NCT07322419 clinical trial?
NCT07322419 is sponsored by Mansoura University. The trial plans to enroll 200 participants.